Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Clinico-pathological and outcome data corresponding to the pancreatic cancer tissue microarray training and validation sets, and the prospective ICGC cohort gene expression array

From: RON is not a prognostic marker for resectable pancreatic cancer

  Training Cohort Validation Cohort ICGC Cohort
Variables n = 76 No. (%) Median DSS (months) P value (Logrank) n = 316 No. (%) Median DSS (months) P value (Logrank) n = 100 No. (%) Median DSS (months) P value (Logrank)
Sex          
  Male 45 (59.2) 16.3   157 (49.7) 18.3   61 (61.0) 18.4  
  Female 31 (40.8) 8.5 0.0340 159 (50.3) 16.9 0.5792 39 (39.0) 18.3 0.5467
Age (years)          
  Mean 62.1    66.7    66.9   
  Median 64.5    69.0    68.0   
  Range 35.0 – 83.0    28.0 – 87.0    34.0 – 90.0   
Outcome          
  Follow-up (months) 0.3 – 158.0    0.1 – 195.8    0.1 – 29.8   
  Median follow-up 158.0    68.7    14.1   
  Death PC 68 (89.5)    259 (82.0)    33 (33.0)   
  Death other 5 (6.6)    15 (4.7)    9 (9.0)   
  Death Unknown 0 (0.0)    3 (0.9)    3 (3.0)   
  Alive 1 (1.3)    38 (12.0)    55 (55.0)   
  Lost to FU 2 (2.6)    1 (0.3)    0 (0.0)   
Stage a          
  I 16 (21.1) 19.6   23 (7.3) 41.0   8 (8.0) 17.4  
  II 59 (77.6) 11.5   282 (89.2) 17.8   87 (87.0) 18.8  
  III 0 (0.0)    0 (0.0)    1 (1.0) ----b  
  IV 1 (1.3) 22.0 0.2828 11 (3.5) 7.6 <0.0001 4 (4.0) 12.0 ****c
T Stage          
  T1 12 (15.8)    16 (5.1)    3 (3.0)   
  T2 29 (38.2) 13.6   33 (10.4) 26.6   12 (12.0) 17.4  
  T3 35 (46.1) 14.7 0.4857 267 (84.5) 16.8 0.0084 84 (84.0)   
  T4 0 (0.0)    0 (0.0)    1 (1.0) 18.4 0.4297
N Stage          
  N0 37 (48.7) 19.8   119 (37.7) 21.2   24 (24.2) 17.4  
  N1 39 (51.3) 9.7 <0.0001 197 (62.3) 16.7 0.0267 75 (75.8) 18.4 0.4714
Grade          
  I 7 (9.2)    26 (8.2)    4 (4.0)   
  II 43 (56.6) 15.0   209 (66.1) 17.7   61 (61.0) ----  
  III 26 (34.2) 11.2 0.0283 81 (25.6) 18.3 0.5971 33 (33.0)   
  IV        2 (2.0) 15.1 0.0011
Tumor size          
  ≤ 20 mm 15 (19.7) 17.1   77 (24.6) 32.0   14 (14.0) 18.3  
  > 20 mm 61 (80.3) 11.9 0.1232 236 (75.4) 16.0 <0.0001 86 (86.0) 18.4 0.8056
Margins          
  Clear 40 (52.6) 18.6   195 (61.7) 22.4   66 (66.0) ----  
  Involved 36 (47.4) 9.7 0.0004 121 (38.3) 13.3 <0.0001 34 (34.0) 13.9 0.0335
Tumor Location          
  Head 62 (81.6) 15.6   258 (81.6) 18.8   85 (85.0) 18.4  
  Others 14 (18.4) 7.4 0.0004 58 (18.4) 13.0 0.0312 15 (15.0) 13.6 0.0488
Perineural Invasion          
  Negative 24 (32.0) 15.6   82 (26.6) 25.6   20 (20.6) ----  
  Positive 51 (68.0) 13.6 0.1909 226 (73.4) 17.4 0.1180 77 (79.4) 17.4 0.0211
Vascular Invasion          
  Negative 45 (60.0) 15.0   161 (53.5) 21.2   39 (40.6) ----  
  Positive 30 (40.0) 10.1 0.0141 140 (46.5) 16.2 0.0070 57 (59.4) 15.9 0.0348
Adj Chemotherapy          
  Yes 13 (17.1) 13.6   98 (31.0) 22.4   65 (68.4) 21.4  
  No 63 (82.9) 14.1 0.7737 218 (69.0) 16.5 0.0451 30 (31.6) 12.0 0.0007
RON Expression d          
  Low or absent 51 (79.7) 15.0   265 (94.3) 17.1   42 (52.5) 9.8  
  High 13 (20.3) 6.4 0.0409 16 (5.7) 18.3 0.2799 38 (47.5) 8.0 0.3830
  1. Patient Cohorts Characteristics.
  2. a AJCC 7th Edition.
  3. b Median survival has not been reached yet.
  4. c Rank test cannot be tested as one or more groups contained no censored observations.
  5. d High RON expression was defined as H > 210 for immunohistochemistry or greater than 8.74 on normalized Log2 score for gene expression array.